Femasys Names John Canning as New Chief Operating Officer

Femasys ( (FEMY) ) just unveiled an announcement.

On April 1, 2026, Femasys Inc. announced it had appointed veteran medical device executive John Canning as chief operating officer, effective March 30, 2026, as the company scales commercialization of its fertility and permanent birth control portfolio. Canning, who previously led global operations and technology at Terumo Aortic and held senior posts at Bolton Medical and Medtronic, is expected to strengthen Femasys’ operational execution and support its global growth strategy as it advances adoption of products such as FemBloc and FemaSeed.

In connection with his appointment, Canning entered into an employment agreement that provides a $450,000 base salary, eligibility for an annual bonus targeted at 40% of salary and participation in standard employee benefit plans. He also received an inducement stock option for 150,000 Femasys shares granted outside the company’s equity plan, vesting over four years and structured to align his incentives with long-term shareholder value, alongside severance protections if terminated without cause or for good reason.

The most recent analyst rating on (FEMY) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Spark’s Take on FEMY Stock

According to Spark, TipRanks’ AI Analyst, FEMY is a Neutral.

The score is held down primarily by weak financial performance (ongoing losses and negative cash flow). Technicals remain soft-to-neutral with a negative MACD and price below key longer-term averages. Corporate events are mixed—FDA and commercialization progress are positives, but listing-compliance risk offsets much of that support.

To see Spark’s full report on FEMY stock, click here.

More about Femasys

Femasys Inc. is a biomedical innovator focused on making fertility treatments and non-surgical permanent birth control more accessible and cost-effective for women worldwide. The U.S.-based manufacturer operates with global regulatory approvals and is commercializing products such as FemaSeed, FemSperm and FemVue, as well as FemBloc and its companion diagnostic FemChec in the U.S. and key international markets.

Its portfolio targets in-office therapeutic and diagnostic solutions, including FemaSeed intratubal insemination, which has shown more than double the pregnancy rate of traditional intrauterine insemination in published data. FemBloc, a non-surgical permanent birth control method, secured full regulatory approval in Europe, the U.K. and New Zealand in 2025, with commercialization in select European countries pursued through strategic partnerships.

Average Trading Volume: 758,374

Technical Sentiment Signal: Sell

Current Market Cap: $25M

For detailed information about FEMY stock, go to TipRanks’ Stock Analysis page.